Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAA2 | P54646 | 8/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577831 | 0.88 | DRD2 (0.45) | PRKAA2GPR183MCHR1KCNH2CYP2D6 | |
| SCHEMBL5577323 | 0.87 | KCNH2 (0.46) | MCHR1KCNH2 | |
| SCHEMBL5577441 | 0.84 | MCHR1 (0.45) | PRKAA2CXCR3MCHR1HTR2C | |
| SCHEMBL5577537 | 0.84 | MT-CO2 (0.43) | PRKAA2CXCR3CYP2D6 | |
| SCHEMBL5577324 | 0.83 | PRKAA2 (0.49) | PRKAA2CXCR3GPR183MCHR1CYP2D6 | |
| SCHEMBL5577711 | 0.82 | PRKAA2 (0.46) | PRKAA2CXCR3GPR183MCHR1CYP2D6 | |
| SCHEMBL5577432 | 0.81 | PRKAA2 (0.47) | PRKAA2CXCR3MCHR1KCNH2 | |
| SCHEMBL5577372 | 0.80 | GPR183 (0.44) | PRKAA2GPR183MCHR1HTR2C | |
| SCHEMBL5577660 | 0.79 | CXCR3 (0.48) | PRKAA2CXCR3MCHR1CYP2D6CHRM1 | |
| SCHEMBL5577349 | 0.79 | CHRM3 (0.52) | PRKAA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | PRKAA2 4492/4885CXCR3 32/4885GPR183 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.